Recursion
What they do
Recursion integrates advanced AI with machine learning, creating a sector-defining company in drug discovery and development. Its strategy rests on three core pillars:
- Developing an extensive in-house pipeline, where Recursion bears all R&D costs and retains full upside from successful drugs
- Co-development partnerships with industry leaders such as Roche and Genentech, Sanofi, and Bayer
- Building industry-leading biological and chemical proprietary datasets via wet lab automation and partnerships – now 65 petabytes and growing – to drive new insights in difficult to treat diseases
In 2024, Recursion announced its strategic combination with Exscientia, another leading AI drug discovery company, combining two of the most advanced platforms in the field and significantly expanding its pipeline and capabilities in precision chemistry.
Why Kinnevik is invested
Kinnevik views Recursion as the leading AI-native drug discovery and development company. Its strong capital base, proven execution and ability to scale its platform across both internal and partnered pipelines position it to capture multi-billion-dollar milestone payments in the years ahead.
Of note is its multi-year collaboration with NVIDIA – a groundbreaking effort to build foundational models in biology and chemistry, using the most powerful private supercomputer in the pharma industry.
Key information
- Integrated AI-enabled full stack platform to decode biology, discover new disease targets and design novel therapeutics at scale
- Transforming drug discovery and development, a traditionally slow, costly and inefficient process with a faster, more precise, and data-driven industrialized approach that on average delivers 3x the speed to clinical at half the cost of traditional pharma
News in the quarter
- Reached a fourth milestone in its collaboration with Sanofi in less than 10 months, versus the industry average of 18-24 months, demonstrating Recursion’s ability to bring greater speed and efficiency through its AI-powered platform
- Announced the release of Boltz-2, a next-generation open-source AI model jointly modeling complex structures and binding affinities. In collaboration with MIT, and powered by Recursion’s NVIDIA supercomputer, the model achieves similar accuracy to commercial products in the space at 1,000x the speed
